• Oxaliplatin in Preclinical Oncology: Mechanisms and Synergis

  2026-05-14

  Explore the advanced mechanisms of Oxaliplatin, a platinum-based chemotherapeutic agent, with a focus on its synergy with novel sensitizers and its expanding utility in cancer biology research. Gain practical insights for optimizing assay design and translational applications.

• Sulfamonomethoxine (SKU BA1078): Reliable Solutions for Lab

  2026-05-13

  This article provides a scenario-driven, evidence-based guide for using Sulfamonomethoxine (SKU BA1078) in cell viability and environmental toxicity assays. It addresses real laboratory challenges, supports protocol optimization, and compares vendor reliability—empowering researchers to achieve reproducible and sensitive results with confidence.

• Toremifene Citrate: Mechanism, Efficacy, and Clinical Parame

  2026-05-13

  The reference study elucidates Toremifene Citrate’s dual estrogen receptor modulatory activity and documents its clinical equivalence to tamoxifen for postmenopausal women with advanced breast cancer. Key insights include its pharmacokinetics, safety profile, and implications for hormone receptor-positive tumor management.

• BRD4 Inhibitors Enhance Erastin-Induced Ferroptosis via ROS

  2026-05-12

  This study demonstrates that BRD4 inhibition, including with I-BET-762, broadly sensitizes diverse cancer cell lines to erastin-induced ferroptosis by increasing reactive oxygen species (ROS) and downregulating FSP1. The findings clarify mechanistic links between BET inhibition and ferroptosis, informing translational strategies in cancer biology and drug resistance.

• JNJ-26481585 (Quisinostat): Potent HDAC Inhibitor for Tumor

  2026-05-12

  JNJ-26481585 (Quisinostat) is a second-generation HDAC inhibitor with sub-nanomolar potency against class I and selected class II HDACs. It induces tumor suppressor gene activation, cell cycle arrest, and apoptosis in diverse cancer models. Recent evidence supports its role in overcoming drug resistance by targeting TRIM21-mediated pathways.

• Nerve-Dependent HDAC1 Regulation in Axolotl Limb Regeneratio

  2026-05-11

  This study uncovers a nerve-mediated, bi-phasic upregulation of HDAC1 as essential for blastema formation and successful limb regeneration in axolotls. Pharmacological inhibition of HDAC activity using MS-275 (Entinostat) or TSA blocks regeneration, highlighting HDAC1 as a key epigenetic regulator linking nerve signals to regenerative capacity.

• EZH2 Maintains Epithelial Identity by Repressing Mesenchymal

  2026-05-11

  Gallardo et al. demonstrate that EZH2, the catalytic subunit of PRC2, directly represses mesenchymal gene expression to uphold the epithelial state in breast carcinoma cells. This work clarifies a conserved epigenetic mechanism underlying cancer cell plasticity, with implications for cancer epigenetics research and targeted inhibition strategies.

• Precision Mapping of Mitochondrial Pore Dynamics: The K2061

  2026-05-10

  Explore how the Mitochondrial Permeability Transition Pore Assay Kit enables nuanced, quantitative analysis of mitochondrial pore dynamics using the Calcein AM fluorescent probe. This article delivers deeper insight into assay selection and the translational impact of mitochondrial permeability assessment.

• M344 Histone Deacetylase Inhibitor: Applied Workflows & Opti

  2026-05-09

  M344 stands out as a potent, cell-permeable histone deacetylase inhibitor, enabling precise epigenetic modulation in cancer and viral latency research. This guide distills experimental protocols, troubleshooting strategies, and evidence-based insights to help researchers leverage M344 for advanced oncology and HIV-1 latency applications.

• Tubastatin A Limits Myocardial Injury Post-Cardiac Arrest in

  2026-05-08

  A recent experimental study demonstrates that Tubastatin A, a potent and selective HDAC6 inhibitor, alleviates myocardial damage following cardiac arrest and resuscitation in a porcine model. The findings highlight the compound’s capacity to reduce pyroptosis and necroptosis in cardiac tissue, offering mechanistic insight for future translational research.

• Hexa His Tag Peptide: Engineering Next-Generation Protein Pu

  2026-05-08

  Discover how the Hexa His tag peptide enables precision control in 6X His-tagged protein purification and interaction analysis. This article uniquely explores the interplay between recombinant protein metal binding and advanced assay design, with actionable insights for molecular biologists.

• CUDC-907: Technical Guide for Dual PI3K and HDAC Inhibition

  2026-05-07

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro research on cell cycle arrest and apoptosis in cancer models. It should not be used for diagnostic or clinical applications or outside established cell-based assay workflows.

• JC-1 Fluorescent Probe: Precision Mitochondrial Membrane Ass

  2026-05-07

  JC-1 stands as the gold standard for mitochondrial membrane potential assays, enabling precise detection of mitochondrial integrity and apoptosis in live cells. This guide details stepwise workflows, experimental enhancements, and troubleshooting strategies to maximize JC-1’s reliability in advanced cellular bioenergetics and dysfunction research.

• NADH (Reduced Nicotinamide Adenine Dinucleotide) in Mitochon

  2026-05-06

  NADH (reduced nicotinamide adenine dinucleotide) is a key coenzyme for cellular energy metabolism and redox balance. Its quantifiable role as an electron donor in mitochondrial electron transport chain research enables precise modeling of metabolic and disease processes. APExBIO’s NADH (CAS No. 58-68-4) is rigorously characterized for research reproducibility.

• Apicidin: Precision HDAC Inhibition and Assay Design Insight

  2026-05-06

  Explore Apicidin, a selective histone deacetylase inhibitor, in-depth. This article provides advanced guidance for assay optimization and addresses nuanced biological effects, setting it apart from existing discussions.

16675 records 1/1112 page Next 12345 下5页 Last page